myTomorrows and Rare Disease Research Unite to Enhance Rare Disease Trial Access

myTomorrows and Rare Disease Research Collaboration

In a significant stride towards enhancing access to clinical trials for patients with rare diseases, myTomorrows has announced a partnership with Rare Disease Research (RDR). The two organizations aim to simplify how patients can be identified and referred to clinical studies, particularly benefiting those with rare conditions. This move addresses the challenges that patients face—such as complex eligibility criteria and limited visibility into existing studies—by establishing a more structured referral system.

The Need for Improved Coordination

Patients suffering from rare diseases often encounter significant hurdles when trying to find suitable clinical trials. The complexities involved include navigating intricate eligibility requirements and the swift evolution of recruitment demands. Furthermore, many referring physicians lack effective avenues to connect potential candidates with specialized research sites.

To counteract these frustrations, the partnership will leverage the myTomorrows platform, which allows referring physicians and specialist care providers to easily identify appropriate RDR trials. This initiative is initially rolling out in sites across Georgia, Florida, and North Carolina, but has the potential to expand further.

Streamlining the Referral Process

The emphasis on structured referrals is key to improving the experience for patients and their families. With the myTomorrows platform, referring providers will submit well-organized referrals directly to RDR site teams. This technology aids in matching patient profiles against study requirements before submissions reach the research teams—thereby increasing the likelihood that treated patients qualify for the trials.

Once a submission is made, referring providers will engage with the RDR clinical research staff through a centralized system. This setup aims to eliminate fragmented communication and establish clearer pathways for current eligible patients, effectively diminishing administrative burdens.

A Focus on Patient-Centric Care

Both myTomorrows and RDR are committed to ensuring that the individual's needs remain at the forefront of this initiative. By providing resources that help families understand available trial options and offering support with the referral procedures, the partnership intends to facilitate smoother transitions for patients seeking to join clinical research.

RDR's CEO, Dr. Han C. Phan, emphasized the importance of this collaboration: "By enhancing our ability to connect with patients effectively through their existing healthcare providers, we can significantly streamline the process. Structured referrals ensure that we can focus our efforts on candidates who are most suited for specific studies, ultimately enhancing the experience for patients and families."

Dr. Michel van Harten, CEO of myTomorrows, elaborated on the project's goals: "Our aim is to digitize and simplify complex recruitment workflows that can slow patient access to these important trials. With a structured referral process, we anticipate significant improvements in operational efficiency, leading to quicker and easier patient engagement."

Enhancing Visibility and Reducing Friction

The framework established by this alliance not only fosters better communication between contrasting healthcare entities and the clinical sites but also prioritizes patient-centric strategies. By creating a more visible and streamlined referral pathway, the goal is to reduce the administrative strain in handling referrals, ensuring that healthcare providers spend their time supporting those who qualify for ongoing studies.

Beyond simply increasing trial accessibility, this collaboration sets the stage for enhancing the overall quality of referrals made to clinical trials. The initiative promises to curate a more effective approach to connecting patients with research that could significantly benefit their health outcomes.

We look forward to witnessing the positive impacts of this partnership as it unfolds, ultimately improving the lives of countless individuals stricken by rare diseases.

About myTomorrows

Founded with the mission to break down barriers, myTomorrows has become an essential player in health technology. With proprietary solutions designed to navigate global public registries for clinical trials and Expanded Access Programs, they aim to simplify access to experimental treatments.

Operating out of Amsterdam and New York City, myTomorrows has positively impacted over 17,700 patients through their innovative technology.

About Rare Disease Research

Rare Disease Research is dedicated to independent clinical research, focusing on rare diseases. By collaborating with various stakeholders, they strive to expand access to clinical trials and uphold robust study execution.